<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849068</url>
  </required_header>
  <id_info>
    <org_study_id>INAF-B13-04-1195</org_study_id>
    <nct_id>NCT01849068</nct_id>
  </id_info>
  <brief_title>Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study</brief_title>
  <acronym>EZEmRNA</acronym>
  <official_title>Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ezetimibe has been shown to inhibit cholesterol absorption and several lines of evidence from
      in vitro systems and animal models suggest that this effect is associated with an increase in
      low-density lipoprotein (LDL) receptor expression in the small intestine. The impact of a
      treatment with ezetimibe on intestinal gene expression and protein mass levels of LDL
      receptor and other key genes involved in intestinal cholesterol homeostasis will be examined
      in dyslipidemic men with insulin-resistance. In the present study, gene expression studies
      and protein mass levels will be assessed on duodenal biopsies by real-time polymerase chain
      reaction (rt-PCR) and liquid chromatography-mass spectrometry (LC-MS/MS), respectively. The
      primary objective of this proposal is to examine the effects of ezetimibe on intestinal gene
      expression (rt-PCR) and protein mass levels (LC-MS/MS) of LDL receptor in dyslipidemic men
      with insulin-resistance. The secondary objective is to examine the impact of ezetimibe
      treatment on intestinal gene expression and protein mass levels of sterol regulatory
      element-binding protein (SREBP)-2, Niemann-Pick C1-Like1 (NPC1L1), ATP binding cassette gene
      (ABCG)-5/8, proprotein convertase subtilisin/kexin type 9 (PCSK9) and
      3-hydroxy-3-methyl-glutaryl-CoA (HMG CoA) reductase.

      Primary hypothesis Treatment with ezetimibe 10 mg/day will significantly increase duodenal
      mRNA and protein mass levels of LDL receptor in dyslipidemic men with insulin-resistance.

      Secondary hypothesis Treatment with ezetimibe 10 mg/day will significantly increase duodenal
      mRNA and protein mass levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA reductase in
      dyslipidemic men with insulin-resistance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions</measure>
    <time_frame>At the end of the two 12-week interventions (Week 12 and 24)</time_frame>
    <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Intestinal mRNA Expression Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions</measure>
    <time_frame>At the end of the two 12-week interventions (Week 12 and 24)</time_frame>
    <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intestinal Protein Levels of LDL Receptor Between the Two 12-week Interventions</measure>
    <time_frame>At the end of the two 12-week interventions (Week 12 and 24)</time_frame>
    <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Protein Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions</measure>
    <time_frame>At the end of the two 12-week interventions (Week 12 and 24)</time_frame>
    <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 10 mg/d for 12 weeks</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>Ezetrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged between 18-60 years

          -  Waist circumference &gt; 102 cm

          -  HDL-cholesterol &lt; 1.1 mmol/L

          -  Triglycerides &gt; 1.7 mmol/L

          -  Fasting blood glucose &gt; 6.1 mmol/L

          -  Normal blood pressure (&lt;130/85)

        Exclusion Criteria:

          -  Women

          -  Men &lt; 18 or &gt; 60 years

          -  Smokers (&gt; 1 cigarette/day)

          -  Body weight variation &gt; 10% during the last 6 months prior to the study baseline

          -  Subjects with a previous history of cardiovascular disease

          -  Subjects with type 2 diabetes

          -  Subjects with a monogenic dyslipidemia

          -  Subjects on hypertension medications or medications known to affect lipoprotein
             metabolism or the integrity of gastrointestinal mucosa

          -  Subjects with endocrine or gastrointestinal disorders

          -  History of alcohol or drug abuse within the past 2 years

          -  Subjects who are in a situation or have any condition that, in the opinion of the
             investigator, may interfere with optimal participation in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Couture, MD, FRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <results_first_submitted>February 15, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2016</results_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Patrick Couture</investigator_full_name>
    <investigator_title>MD, FRCP, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe First, Then Placebo</title>
          <description>First intervention: Ezetimibe 10 mg/d for 12 weeks Second intervention: Placebo for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Ezetimibe</title>
          <description>First intervention: Placebo for 12 weeks Second intervention: Ezetimibe 10 mg/d for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe First Then Placebo</title>
          <description>First intervention: Ezetimibe 10 mg/d for 12 weeks Second intervention: Placebo 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo First Then Ezetimibe</title>
          <description>First intervention: Placebo for 12 weeks Second intervention: Ezetimibe 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="7.9"/>
                    <measurement group_id="B2" value="39.4" spread="13.6"/>
                    <measurement group_id="B3" value="39.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions</title>
        <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
        <time_frame>At the end of the two 12-week interventions (Week 12 and 24)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe: Ezetimibe 10 mg/d for 12 weeks Ezetimibe 10 mg/d for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo for 12 weeks Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions</title>
          <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
          <units>#copies/100000 copies housekeeping gene</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110531" spread="32604"/>
                    <measurement group_id="O2" value="95140" spread="31840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Intestinal mRNA Expression Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions</title>
        <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
        <time_frame>At the end of the two 12-week interventions (Week 12 and 24)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe: Ezetimibe 10 mg/d for 12 weeks Ezetimibe 10 mg/d for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo for 12 weeks Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intestinal mRNA Expression Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions</title>
          <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
          <units>#copies/100000 copies housekeeping gene</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HMGCoA reductase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354911" spread="102607"/>
                    <measurement group_id="O2" value="311268" spread="88237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCSK9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9079" spread="5816"/>
                    <measurement group_id="O2" value="8091" spread="6131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SREBP-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193012" spread="32787"/>
                    <measurement group_id="O2" value="182349" spread="36681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NPC1L1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454298" spread="97707"/>
                    <measurement group_id="O2" value="448686" spread="138746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCG5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271811" spread="111688"/>
                    <measurement group_id="O2" value="283863" spread="132434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCG8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125315" spread="46842"/>
                    <measurement group_id="O2" value="129551" spread="63246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Intestinal Protein Levels of LDL Receptor Between the Two 12-week Interventions</title>
        <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
        <time_frame>At the end of the two 12-week interventions (Week 12 and 24)</time_frame>
        <population>Data will never be analyzed because the mRNA expression of LDL receptor is sufficient.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe: Ezetimibe 10 mg/d for 12 weeks Ezetimibe 10 mg/d for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo for 12 weeks Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intestinal Protein Levels of LDL Receptor Between the Two 12-week Interventions</title>
          <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
          <population>Data will never be analyzed because the mRNA expression of LDL receptor is sufficient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Protein Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions</title>
        <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
        <time_frame>At the end of the two 12-week interventions (Week 12 and 24)</time_frame>
        <population>Data will never be analyzed because the mRNA expression of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA reductase are sufficient.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe: Ezetimibe 10 mg/d for 12 weeks Ezetimibe 10 mg/d for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo for 12 weeks Placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Protein Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions</title>
          <description>We combined the results at the end of each ezetimibe phase from both sequence (average and standard deviation).
We combined the results at the end of each placebo phase from both sequence (average and standard deviation).</description>
          <population>Data will never be analyzed because the mRNA expression of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA reductase are sufficient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe</title>
          <description>Ezetimibe 10 mg/d for 12 weeks Ezetimibe 10 mg/d for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo for 12 weeks Placebo for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patrick Couture MD, PhD, FRCP</name_or_title>
      <organization>Laval University</organization>
      <phone>418-654-2106</phone>
      <email>patrick.couture@crchul.ulaval.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

